ReviewEuropean journal of pain (London, England)2026
Towards a Whole-Body Assessment of Pain Using the 18 kDa Translocator Protein (TSPO) as a Broad-Spectrum Imaging Marker of Inflammation.
Review in European journal of pain (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveChronic pain is increasingly understood as a systemic condition involving coordinated immune responses across central and peripheral compartments. In this narrative review, we present evidence supporting positron emission tomography (PET) imaging of the translocator protein (TSPO), long considered a marker of neuroinflammation, as a promising tool to visualize inflammation throughout the body. DATABASES AND DATA TREATMENT: This narrative review synthesizes published evidence from TSPO PET studies in chronic pain. We first provide a concise overview of central nervous system (CNS) applications across various chronic pain conditions, implicating neuroinflammation as a potential pathophysiological mechanism underlying human chronic pain. We then discuss evidence from studies extending this imaging approach beyond the CNS to peripheral tissues, in which TSPO is highly expressed by immune cells. We also review associations between these imaging signals, clinical measures and circulating cytokine levels.
resultsCompared with controls, patients with chronic pain show elevations in TSPO PET signal not only within the CNS, including the brain and spinal cord, but also in peripheral structures such as the neuroforamina and joints. Correlations with clinical measures and systemic cytokine levels underscore the potential clinical significance of these peripheral signals. This expanded view positions TSPO PET as a broad-spectrum marker of inflammation, enabling a unified imaging modality that bridges traditionally siloed approaches to pain research, while also facilitating the discovery of previously underappreciated pain-relevant tissues and immune compartments. Of particular relevance, the application of TSPO PET beyond its traditional CNS focus has revealed a previously unrecognized role for CNS-adjacent immune niches, such as skull bone marrow, in human chronic pain.
conclusionsWith further evaluation, TSPO PET may provide a means of visualizing inflammatory processes across multiple pain-relevant compartments, paving the way for a whole-person approach to the study of human chronic pain. SIGNIFICANCE: TSPO PET is not merely a neuroimaging tool but could serve as a systemic marker of inflammation in chronic pain. By enabling a whole-person framework for studying pain and inflammation, it has the potential to inform precision medicine approaches and guide therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.